Yoon Young Cho1, Hye Won Jang2, Ju Young Jang1, Tae Hyuk Kim1, Jun-Ho Choe3, Jung-Han Kim3, Jee Soo Kim3, Sun Wook Kim1, Jae Hoon Chung4. 1. Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Medical Education, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. Department of Surgery, Division of Breast and Endocrine Surgery, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. thyroid@skku.edu.
Abstract
BACKGROUND: Persistent hypercalcitoninemia is reported in 40% to 60% of patients with medullary thyroid cancer (MTC) after initial therapy, but their clinical outcomes have not been clearly studied. We evaluated the outcomes of MTC with hypercalcitoninemia and assessed the cutoffs of postoperative serum calcitonin for predicting structural recurrence. METHODS: A dynamic risk assessment system was used to categorize clinical outcomes in this retrospective study. Receiver operating characteristic (ROC) curve analysis was used to calculate the calcitonin cutoffs for predicting structural recurrence. RESULTS: Among 120 patients operated on, 30 (25%) had persistent hypercalcitoninemia. Of that group, 18 (60%) had biochemical persistent disease and 11 (37%) developed structural identified disease, including 1 death (3%). Postoperative calcitonin <29 pg/mL predicted structural disease with 100% sensitivity, 90.5% specificity, and 100% negative predictive value. CONCLUSION: One third of the patients with MTC with hypercalcitoninemia experienced structural recurrence, and postoperative basal serum calcitonin might be a simple tumor marker to predict structural recurrence.
BACKGROUND: Persistent hypercalcitoninemia is reported in 40% to 60% of patients with medullary thyroid cancer (MTC) after initial therapy, but their clinical outcomes have not been clearly studied. We evaluated the outcomes of MTC with hypercalcitoninemia and assessed the cutoffs of postoperative serum calcitonin for predicting structural recurrence. METHODS: A dynamic risk assessment system was used to categorize clinical outcomes in this retrospective study. Receiver operating characteristic (ROC) curve analysis was used to calculate the calcitonin cutoffs for predicting structural recurrence. RESULTS: Among 120 patients operated on, 30 (25%) had persistent hypercalcitoninemia. Of that group, 18 (60%) had biochemical persistent disease and 11 (37%) developed structural identified disease, including 1 death (3%). Postoperative calcitonin <29 pg/mL predicted structural disease with 100% sensitivity, 90.5% specificity, and 100% negative predictive value. CONCLUSION: One third of the patients with MTC with hypercalcitoninemia experienced structural recurrence, and postoperative basal serum calcitonin might be a simple tumor marker to predict structural recurrence.
Authors: Hosu Kim; Young Nam Kim; Hye In Kim; So Young Park; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Jae Hoon Chung; Tae Hyuk Kim; Sun Wook Kim Journal: Sci Rep Date: 2017-12-05 Impact factor: 4.379
Authors: Hyunju Park; So Young Park; Jun Park; Jun Ho Choe; Man Ki Chung; Sook-Young Woo; Joon Young Choi; Sun Wook Kim; Jae Hoon Chung; Tae Hyuk Kim Journal: Front Endocrinol (Lausanne) Date: 2021-10-05 Impact factor: 5.555